• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals
Postgrad Med. 2022 Aug 25. doi: 10.1080/00325481.2022.2117498. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States. Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal risk factor for ASCVD. Current evidence overwhelmingly demonstrates that lowering LDL-C reduces the risk of secondary cardiovascular events in patients with previous myocardial infarction or stroke. There is no lower limit for LDL-C: large, randomized studies and meta-analyses have found continuous benefit and no safety concerns in patients achieving LDL-C levels &...
Source: Postgraduate Medicine - August 25, 2022 Category: Internal Medicine Authors: James Underberg Peter P Toth Fatima Rodriguez Source Type: research

Perceptions and knowledge gaps on CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc score components: a joint survey of Chinese clinicians and clinical pharmacists
CONCLUSIONS: Chinese medical professionals, especially EPs and GPs, revealed a lack of knowledge and insufficient skills for CHA2DS2-VASc scores and their components. Improvements in the awareness of the CHA2DS2-VASc score and its detailed scoring criteria are urgently needed for Chinese medical professionals. Therefore, education programs concerning the introduction of stroke risk evaluation for AF patients and the development of referencing scoring tools are necessary.PMID:34694951 | DOI:10.1080/00325481.2021.1996815
Source: Postgraduate Medicine - October 25, 2021 Category: Internal Medicine Authors: Chi Zhang Long Shen Mang-Mang Pan Ying-Li Zheng Zhi-Chun Gu Hou-Wen Lin Source Type: research

Defining Metabolic Syndrome and Factors Associated with Metabolic Syndrome in a Poly-pharmaceutical Population.
CONCLUSION: The IDF definition for METs that makes allowance for treatment for each specific condition can lead to an overestimation in the prevalence of METs in population studies. Not including those medicated with normal results conversely underestimates the prevalence of METs. We have therefore proposed adjustments to BP and lipid measurements based on pooled mean effects from published systematic reviews to mitigate bias in future research on prevalence of METs. PMID: 27558757 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - August 27, 2016 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Underuse of Anticoagulation in Patients with Atrial Fibrillation.
Authors: Vallakati A, Lewis WR Abstract Atrial fibrillation (AF) is a major risk factor for ischemic stroke. Guidelines recommend anticoagulation for patients with intermediate and high stroke risk (CHA2DS2-VASc score ≥2). Underuse of anticoagulants among eligible patients remains a persistent problem. Evidence demonstrate that the psychology of the fear of causing harm (omission bias) results in physicians' hesitancy to initiate anticoagulation and results in an inaccurate estimation of stroke risk. The American Heart Association (AHA) initiated the Get With The Guidelines-AFIB (GWTG-AFIB) module in June 2013 to...
Source: Postgraduate Medicine - December 20, 2015 Category: Internal Medicine Tags: Postgrad Med Source Type: research